32 results about "Polymeric drug" patented technology

This invention discloses a biodegradable brush-shaped polymer drug carrier and its applications, belonging to the field of polymer compound technology. The brush-shaped polymer drug carrier is obtained by a click reaction between a polydisulfide backbone and cationic side chains. The polydisulfide backbone in its structure can undergo a special "sulfhydryl exchange" reaction with free thiol groups present on cell membrane proteins, directly carrying the nucleic acid drug into the cell through the cell membrane, thus completing the delivery of the nucleic acid drug. After entering the body, under the action of glutathione (GSH) which is abundant in the tumor cell cytoplasm, the polydisulfide backbone is broken and degraded, releasing the nucleic acid drug, which is suitable for the delivery of nucleic acid drugs.

A polymeric scaffold for binding to a targeting moiety to form a targeting moiety-polymer-drug conjugate. A targeting moiety-polymer-drug conjugate is provided, which is prepared from the stent. The composition comprises the combination. A method of treating various conditions with the conjugate or the composition, comprising administering the conjugate or the composition.

The invention discloses a hybrid cell membrane modified bionic nanoparticle with an anti-tumor effect and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the bionic nanoparticle comprises a nanoparticle core and a hybrid cell membrane coating the nanoparticle core; the nanoparticle core comprises an amphiphilic polymer drug carrier and an active drug, and the active drug comprises a photo-thermal agonist TPT and an STING agonist DMXAA; the hybrid cell membrane is formed by co-extruding and hybridizing a cancer cell membrane and a macrophage membrane. The STING agonist DMXAA and the photo-thermal agonist TPT synergistically play a role, heat can be generated under near-infrared laser irradiation to kill cancer cells and induce immunogenic death of the cancer cells, and an injury-related molecular pattern is released, so that DMXAA-mediated immunotherapy is activated, and the anti-tumor effect is achieved.

A drug development assistance device comprising a processor, wherein the processor predicts a stable range in which the stability of a large molecule drug is equal to or higher than a set level for a first condition which is one among a plurality of conditions related to the composition of a preservation solution for the large molecule drug.

The present invention is directed to polymer-drug conjugates and / or compositions and / or nanoparticles comprising anti-cancer agents. The present invention is also directed to polymer- drug conjugates and / or compositions comprising docetaxel and the administration of docetaxel derivatives for the treatment of a number of diseases. The present invention is also directed to polymer-drug conjugates and / or compositions comprising gemcitabine or combretastatin A4 for the treatment of a number of diseases.

This invention relates to polymer drug conjugates according to formula I, and their use for treatment of diseases such as cancer.

To provide a novel drug delivery system.SOLUTION: A polymer drug complex for use in a drug delivery system employing platelets as a drug carrier, the polymer drug complex comprising (A) a cationic polymer and (B) an anti-inflammatory drug, where the (A) cationic polymer and the (B) anti-inflammatory drug are bound to each other.SELECTED DRAWING: None

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The present disclosure relates to the delivery of multiple copies of a payload molecule such as an active agent or a chelating agent capable of capturing an active agent, using as a carrier for their delivery a biocompatible copolymer comprising side chain-linked amino acids functionalized at their alpha-amino group by a reactive azide moiety by means of which the payload molecules are coupled to the copolymer. The copolymer is typically further functionalized to contain a single copy of a cell type- or tissue type-specific targeting moiety.

The invention belongs to the field of external medicines for pets, and provides a macromolecular medicine carrier for treating cat tinea, which is prepared by adopting a collaborative design of core-shell nanogel particles and a double-state antibacterial component and through stepwise reaction of hexamethylene diisocyanate, polyethylene glycol, polyethylene glycol diamine and a silane coupling agent. A core-shell structure with the particle size of 100-350 nm and the shell thickness of 5-30 nm is formed through water dispersion emulsification and silane hydrolytic condensation, and a Si-O-Si bond fixed state and non-covalent releasable state antibacterial mechanism is constructed by combining polyhexamethylene biguanide hydrochloride. According to the invention, the powerful antibacterial property of the minimal inhibitory concentration of 0.2-3.00 mg / mL to pathogenic dermatophyte is realized, a low-viscosity processing window and skin-friendly pH value are kept at 5.5-7.5, the coupling problem of high load, long-acting washing resistance, rapid effect and continuous inhibition and film-forming adhesion durability of an external preparation is solved, and the preparation has wide application value.

This disclosure is directed to a pharmaceutical composition comprising sodium bicarbonate and a polymer-drug nanoaggregate having a polymer and a taxane. The polymer is water soluble and comprises at least one first terminal group modified with a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. The taxane can include paclitaxel, docetaxel, cabazitaxel, larotaxel, milataxel, ortataxel, tesetaxel, derivatives therefrom or a combination thereof, which are water insoluble or poorly water soluble. Such polymer-drug nanoaggregates can improve drug solubility, stability, in vivo availability and efficacy, and reduce side effects such as renal toxicity. This invention is also directed to a process for producing the pharmaceutical composition comprising the polymer-drug nanoaggregate. This invention is further directed to a method for treating a disease including cancer using the pharmaceutical composition disclosed herein.

The invention relates to a dual drug loaded, targeted polymer drug nanoconjugate affecting multiple signaling pathways for use as a drug delivery system in the treatment of ovarian cancer. Said nanoconjugate comprises Cabozantinib (CBZ) as a VEGFR (Vascular endothelial growth factor receptor) inhibitor and Ki16425 as a LPAR (Lysophosphatidic acid receptor) 1,2,3 inhibitor. In the nanoconjugate of the invention, synergistic effect is obtained with dual drug use.

A triple antibiotic nanofiber scaffold for wound dressings, consisting of: (a) a polymer blend of polyacrylonitrile and pullulan in a weight ratio of about 10:1; (b) one or more fluoroquinolone active ingredients selected from levofloxacin, ciprofloxacin and ofloxacin in different concentrations; wherein the polymer-drug solution is electrospun using a voltage of about 15 kV and a flow rate of about 5 ml / h to form uniform nanofiber mats on a collector covered with aluminum foil, and where the nanofibers are configured to provide structural integrity, drug loading capacity, and potential wound healing properties.

This invention relates to polymer drug conjugates according to formula I, and their use for treatment of diseases such as cancer.

A method of preparing polymer-drug conjugates (PDCs) including reacting a drug-bearing compound such as monomer / oligomer / polymer terminated at both ends by "clickable" functional groups with other monomer / oligomer / polymer bearing complementary "clickable" functional group using suitable ratios of each monomer to form PDCs by click chemistry such as strain-promoted [3+2] azide-alkyne cycloaddition (SPAAC)-mediated step-growth polymerization, and PDCs prepared therefrom. Also disclosed is a method for treating cancers using the PDCs.

Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO3−), sulfuric acid group (—OSO3−), carboxylic group (—CO2−), phosphonic acid group (—OPO32−), phosphate group (—OPO32−), and sulfamic acid group (—NHSO3−). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

The invention relates to the technical field of tumor treatment, and discloses a polymeric drug-loaded particle servo type controlled release system and method based on high-frequency oscillation excitation. The system comprises polymeric drug-loaded particles; the Doppler echo repositioning module is used for acquiring imaging information of the tumor tissue in real time and generating a servo-adjusted sound signal according to the imaging information; the array type ultrasonic unit is in communication connection with the Doppler echo re-positioning module and is used for receiving the sound signal subjected to servo adjustment and transmitting high-frequency ultrasound according to the sound signal; wherein when the high-frequency ultrasound acts on the polymeric drug-loaded particles, the polymeric drug-loaded particles are positioned on target tissues under the dual effects of tumor cell surface receptor targeting and subcellular structure targeting, and the sound-sensitive agent generates active oxygen under the excitation of the high-frequency ultrasound, so that the drug-loaded particles can be used for treating tumor cells. And the array type ultrasonic unit can adjust the ultrasonic excitation intensity in real time according to the imaging of the tumor tissue so as to realize the instantaneous active oxygen filling of the target tissue and reconstruct the tumor microenvironment.

The invention relates to a 7-ethyl-10-hydroxycamptothecin polymer which has a structural formula as shown in (I), R is S or S-S, m is an integer selected from 20-200, and n is an integer selected from 2-40. The 7-ethyl-10-hydroxycamptothecine SN38 is subjected to structural modification by using beta-CD-PEG, and an-S-or-S-S-ligand with a redox function is used as a connecting arm to prepare the amphiphilic polymer-drug conjugate beta-CD-PEG-R-SN38, so that the water solubility and the stability of the SN38 are improved; meanwhile, the beta-CD-PEG-R-SN38 is prepared into self-assembled nanoparticles, and the self-assembled nanoparticles are high in drug loading capacity, moderate in particle size, uniform in dispersion, low in toxicity and good in biocompatibility, and show an obvious tumor growth inhibition effect in cell tumor-bearing nude mouse models of H22 liver cancer, 4T1 mouse breast cancer, SW480 colon cancer, KB oral epidermal cancer and the like.

The invention describes ophthalmic pharmaceutical formulations comprising pharmaceutical ingredients to address DED symptoms. In one aspect of the invention, an ophthalmic pharmaceutical formulation comprises: 1) lubricity-promoting ingredient(s) such as those listed in the FDA over the counter (OTC) monograph for ophthalmics as demulcents and 2) surfactant(s) that solubilize lipids, assist in lubrication, and assist in easily spreading over hydrophobic surfaces; and / or 3) lipid and / or oil ingredient(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication; and / or 4) mucoadhesive and viscosity promoting polymer(s) that demonstrate shear thinning flow behavior. The pharmaceutical ingredients and osmoprotectant / tonicity ingredients are combined with ingredients that provide direct to the eye nutritional support that is comprehensive in nature. The total nutritional approach uses metabolically important tear fluid amino acids, vitamins, natural antioxidants such as ferulic acid, and both fatty acids / triglycerides and sugar molecules as energy sources. The invention results in both improved eye health and improved dry eye patient comfort.

This disclosure is directed to a process for producing a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that is water insoluble or poorly water soluble. The polymer is water soluble and comprises at least one first terminal group modified with H (H) or a hydrophobic moiety (C) and a second terminal group modified with a hydrophilic moiety. The polymer can be a modified symmetrically or asymmetrically branched polymers. This disclosure is further directed to a method for producing a polymer having a pre-defined H / C ratio.

The invention provides a high-molecular polymer drug-loaded particle compound and a related method for reducing local fat, reducing body weight, preventing, treating and lightening skin color and melanin precipitation, and alleviating arthritis symptoms. The high-molecular polymer drug-loaded particle compound comprises at least one active ingredient and high-molecular polymer drug-loaded particles, and the high-molecular polymer drug-loaded particles are used as carriers of the active ingredients to coat the active ingredients so as to form the high-molecular polymer drug-loaded particle compound.

The invention relates to a polymer-drug conjugate with controllable and stable nanometer size, and an intermediate and application thereof. The invention relates to a polymer-drug conjugate which is shown as a formula (I), takes different polymer main bodies, and has controllable group coupling quantity, controllable group coupling sites and controllable nanometer size. The drug conjugate has one or more of the advantages of low kidney clearance rate, low liver and spleen clearance rate, long plasma half-life period, strong focus tissue drug accumulation capacity, strong focus tissue drug infiltration capacity, low toxic and side effects and excellent treatment effect. # imgabs0 #

Methods for preparing polymer-drug conjugates containing a bioactive moiety and a fluorescent or colored dye are provided. The process comprises reacting a compound of structure (I): Formula (I) with an amine-containing bioactive compound of structure (II): wherein G comprises a group capable of forming a covalent bond with an amine group, and R1, R2, R3, R4, R5, R6, R7, R8, L1, L2, L3, L4, L5, L6, L7, M1, m, n, p and w are as defined herein. , (I)

The invention relates to polymer drug conjugate comprising dexamethasone or betamethasone, and methods for preparation of dexamethasone or betamethasone derivatives for the treatment of a number of diseases. Moreover, the embodiments of the invention relate to chemical compounds having an anti-inflammatory activity and / or immunosuppressive activity and synthetic intermediates, means for their preparation, pharmaceutical compositions and drug-delivery systems comprising such compounds including dexamethasone or betamethasone, and methods of treatment employing the same.

This invention relates to polymer drug conjugates comprising a (meth)acrylate based polymer backbone with at least two types of side chains wherein one of the side chains is a PEG chain and the other side chain comprises at least one therapeutic agent covalently bonded to a cleavable linker, methods of preparing said polymer-drug conjugates and their use for treatment of diseases such as cancer.

The invention discloses a mitochondrial targeting nano-composite. The mitochondrial targeting nano-composite is formed by a mitochondrial targeting HPMA polymer-drug conjugate with positive charges and hyaluronic acid with negative charges through electrostatic self-assembly, the mitochondrial targeting HPMA polymer-drug conjugate is a conjugate formed by connecting an HPMA polymer modified by a mitochondrial targeting group DEA and a mitochondrial metabolism inhibitor through a cleavable bond. The invention further discloses a preparation method of the mitochondrial targeting nano-composite and application of the mitochondrial targeting nano-composite in preparation of anti-tumor drugs. According to the invention, hyaluronic acid is specifically combined with a CD44 receptor highly expressed on the surface of a tumor cell, so that active targeting at the tumor cell level is realized; meanwhile, by means of a DEA or GPMA mitochondrial targeting group, the drug is guided to be accurately positioned to tumor cell mitochondria, a dual targeting system of cell targeting and organelle targeting is formed, the enrichment concentration of the drug at an action target spot is greatly improved, and the problems that a traditional drug is weak in targeting property and low in action efficiency are solved.

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I):or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, L, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.

The invention provides traditional Chinese medicine nanoparticles for preventing and treating chicken coccidiosis and a preparation method and application thereof, and relates to the technical field of traditional Chinese veterinary medicines. Wherein the medicine component is composed of a first decoction and a second decoction, the first decoction is obtained by decocting astragalus membranaceus and bighead atractylodes rhizome, the second decoction is obtained by decocting antifebrile dichroa and artemisia apiacea, and the first decoction and the second decoction are respectively combined and concentrated to form a unified medicine component according to a preset proportion; the response carrier comprises succinylated chitosan and an azobenzene derivative cross-linked polymer containing azo bonds, and the drug components are embedded in the response carrier to form the traditional Chinese medicine nanoparticles with core-shell structures; the succinylated chitosan is swelled in an acid environment, and azo bonds are structurally changed under the action of azo reductase, so that the traditional Chinese medicine nanoparticles are easier to release medicine components in a chicken coccidiosis related intestinal environment; the invention further provides a preparation method of the traditional Chinese medicine nanoparticles and application of the traditional Chinese medicine nanoparticles in preparation of veterinary medicine preparations or feed additives for preventing and treating chicken coccidiosis.

An implantable device for delivering a polymeric drug compound is provided. The device includes a core having an outer surface and a membrane layer disposed adjacent to the outer surface of the core. The core includes a core polymer matrix having a drug compound dispersed therein, the polymer matrix containing a hydrophobic polymer. The membrane layer further includes a membrane polymer matrix having the polymeric drug compound optionally dispersed therein. The membrane polymer matrix contains a hydrophobic polymer in combination with a hydrophilic compound, and the weight ratio of hydrophobic polymer to hydrophilic compound within the membrane polymer matrix ranges from about 0.25 to about 200. [Selected Figure] Figure 1

To provide pramlintide analogs that retain amylin agonist activity and have advantages such as extended half-life and reduced tendency to fibrillate.SOLUTION: A polypeptide having a specific sequence, which is a pramlintide analogue conjugated to a half-life extending moiety, such as an albumin binding moiety. The disclosed peptides can be formulated in or chemically conjugated to, for example, proteins, polymeric drug carriers or pre-drug delivery systems, which enhance the chemical and or physical stability and or circulatory exposure of the therapeutic moiety.SELECTED DRAWING: None